Цитрамон Ультра

Quick links

Choose a section

Quick links to important sections

Advertisements

Цитрамон Ультра

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Цитрамон Ультра

What is Tsitramon Ultra? (Quick Facts and Overview)

Property Description
Active Ingredients Acetaminophen, Acetylsalicylic Acid, Caffeine
Form Tablet (Oral administration)
Pharmacological Class Analgesic-Antipyretic Combination
Common Use Symptomatic relief of pain and fever
Origin Synthetic Compound

Identity and Pharmacological Classification

Tsitramon Ultra is a synthetic, multi-component medicinal product classified as a fixed-dose analgesic combination. This preparation falls within the therapeutic class of non-opioid analgesics and antipyretics, with an anti-inflammatory component contributed by Acetylsalicylic Acid (ASA). The drug is intended for oral administration in the form of tablets. Pharmacological evidence supports the clinical recognition of such combinations in providing enhanced pain relief compared to single agents.

Composition and Distinctive Features

The drug’s formulation is defined by its three active ingredients: Acetaminophen (Paracetamol), Acetylsalicylic Acid (Aspirin), and Caffeine. This triple-ingredient formulation is a distinguishing feature of Tsitramon Ultra and similar products. Caffeine acts as an adjuvant, meaning it enhances the pain-relieving effects of the other two ingredients by increasing their absorption and efficacy. Tsitramon Ultra is typically marketed as an Over-the-Counter (OTC) product for adult use, positioning it for quick self-management of common discomforts.

General Purpose and Combined Action

The general purpose of Tsitramon Ultra is to provide a comprehensive approach to symptomatic relief by targeting pain, fever, and associated fatigue simultaneously. This integrated action aims for broader relief, leveraging the synergistic effect where each component assists the others, making it a multi-purpose option intended for the effective management of general discomfort and feverish states.

Advertisements

What side effects are possible with Цитрамон Ультра?

Official Safety Profile and Adverse Reactions

The safety profile for this fixed-dose combination (Acetaminophen, Aspirin, and Caffeine) is categorized by regulatory authorities based on the affected organ system and the frequency of occurrence. Documented adverse reactions are grouped into categories such as Gastrointestinal System/Disorders, Nervous System, and Hepatic System.

Common effects listed in regulatory documents often involve the gastrointestinal tract, such as upset stomach and heartburn, as well as the central nervous system, including nervousness and sleep problems (insomnia).


Serious Adverse Reactions and Safety Constraints

Official labels describe specific serious adverse reactions that require recognition. These include severe liver damage (hepatotoxicity), which is explicitly linked to exceeding the maximum daily amount of Acetaminophen or using the product concurrently with other acetaminophen-containing medications. Additionally, severe gastrointestinal bleeding and the risk of Reye's Syndrome in children and teenagers with viral infections are serious risks associated with the Aspirin component. Rare but documented risks also include severe allergic reactions and severe skin reactions.

Safety constraints are also defined for specific populations. Regulatory text notes that older adults may have an increased sensitivity to side effects, particularly gastrointestinal bleeding. For pregnancy, use is not recommended in the third trimester. A duration-related safety pattern is defined for Medication Overuse Headache, which may occur if the medicine is used for ten or more days per month.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with combination products like Citramon Ultra (typically Acetaminophen/Aspirin/Caffeine) presents complex, time-sensitive risks primarily driven by the Acetaminophen component. All information is based on authoritative government regulatory documentation.

Documented Manifestations and Serious Outcomes

Early signs within the first 24 hours may include nausea, vomiting, pallor, and abdominal pain. These non-specific symptoms are unreliable indicators of severity. The most serious outcome is delayed, potentially fatal hepatic necrosis (liver damage) from Acetaminophen toxicity, which can progress to hepatic failure, coma, and death.

Signs of Salicylate (Aspirin) and Caffeine toxicity, such as tinnitus (ringing in the ears), metabolic acidosis, or cardiac arrhythmias, may also occur.

Required Emergency Actions

Immediate medical attention is required in the event of a suspected overdose, even if the patient feels well. This is due to the critical time window for effective treatment.

  • Antidote: N-acetylcysteine (NAC) is the specific antidote for Acetaminophen poisoning and is most effective when administered within eight hours of ingestion.
  • Monitoring: Plasma Acetaminophen concentration measurements are required at four hours or later post-ingestion to guide treatment decisions.

Individuals with risk factors, such as chronic alcohol use or malnutrition, face a higher hazard of severe liver damage from the Acetaminophen component. Management is focused on supportive care and the prompt use of the specific antidote.

Advertisements

Therapeutic Uses of Цитрамон Ультра

What Цитрамон Ультра treats: Main Uses and Benefits

Relief for Acute Pain and Headache Syndromes

The combination may be part of symptomatic management used in contexts marked by increased discomfort or tension from symptoms related to physical discomfort. The product is commonly used to help with symptoms related to acute or episodic changes in the headache spectrum, including tension-type headache, acute migraine attacks, dental pain, and pain associated with the menstrual cycle (algomenorrhea). This provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort during symptomatic periods.

Management of Fever and Systemic Discomfort

The medication is commonly used to help with managing symptoms related to systemic imbalance, specifically the cluster of elevated body temperature (fever), general malaise, and associated fatigue. It is applied across domains where additional symptomatic support is needed for symptoms related to systemic imbalance, such as fever and malaise in conditions like the common cold. This approach helps address symptom clusters that may become intense or disruptive, providing supportive relief across multiple domains during difficult episodes.


“The intention is to offer symptomatic relief that helps patients cope more steadily with difficult episodes, supporting general well-being during symptomatic phases.”


Quick Fact: Relief for Episodic Discomfort

The medication is commonly used when short-term symptomatic assistance is needed during phases when symptoms become more noticeable, which may help maintain a sense of stability and contributes to easing the overall symptom load during episodes of heightened discomfort.

Regulatory References

  1. NIH DailyMed drug label
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Цитрамон Ультра — Official Regulatory Information

The eligibility profile for Цитрамон Ультра is defined by regulatory bodies based on the contraindications of its three active components: Acetaminophen, Acetylsalicylic Acid (ASA), and Caffeine.

Populations for whom use is contraindicated:

  • Patients with known Hypersensitivity or allergy to any active substance or excipient.
  • Patients with Severe Hepatic or Renal Impairment or active liver disease.
  • Patients with Active Peptic Ulcer Disease or history of gastrointestinal bleeding.
  • Patients with Hemorrhagic Diathesis or severe uncontrolled heart failure.
  • Patients with a history of Aspirin-Induced Asthma or G6PD Deficiency.

Age-Related Eligibility Rules:

  • Pediatric Use: The medicine is not recommended for use in children under the labeled minimum age (typically 12 or 16 years, depending on the label). It is strictly contraindicated in children and adolescents recovering from Viral Infections (e.g., flu, chickenpox) due to the risk of Reye's Syndrome.
  • Older Adults (≥ 65 years): Use requires Special Caution due to an increased risk of adverse effects, particularly gastrointestinal bleeding.

Pregnancy and Lactation Eligibility Status:

  • Pregnancy: The medicine is contraindicated during the Third Trimester due to the ASA component. Use during the first and second trimesters is not recommended.
  • Lactation: Use is not recommended as the active metabolites are excreted into breast milk.

Eligibility-Related Restrictions: Use requires Caution in patients with a history of non-active gastrointestinal disorders, chronic alcoholism, anxiety disorders, or gout. These eligibility rules establish that only eligible adults and adolescents without these specific prohibitions are permitted to use the medicine.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interaction patterns for products containing Acetaminophen, Acetylsalicylic Acid (ASA), and Caffeine, based strictly on government regulatory documents.

Contraindicated Combinations and Exposure Constraints

Co-administration is formally prohibited with several medicinal products due to high interaction risks, primarily focusing on additive toxicity and clearance interference.

  • Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and ASA-Containing Products: This combination is strictly prohibited due to the significantly increased pharmacodynamic risk of serious gastrointestinal events, including bleeding and ulceration.
  • Methotrexate (≥ 15 mg/week): This is contraindicated because the ASA component decreases Methotrexate renal clearance, a pharmacokinetic interaction that increases its plasma concentration and elevates toxicity risk.
  • Monoamine Oxidase Inhibitors (MAOIs): Use during or within 14 days of receiving MAOIs is a prohibited combination due to the Caffeine component's risk of severe hypertension.

Significant Substance and Metabolic Interactions

Regulatory labeling highlights specific interactions that alter drug clearance or enhance systemic toxicity.

  • Alcohol: Concomitant use with alcohol is explicitly documented as an interaction that increases the risk of hepatotoxicity related to Acetaminophen and gastrointestinal bleeding related to ASA.
  • CYP1A2 Inhibitors (e.g., Ciprofloxacin): These are documented to cause a significant reduction in the metabolic clearance of the Caffeine component, which is a pharmacokinetic interaction leading to increased plasma exposure.
  • Anticoagulants (e.g., Warfarin): Co-administration is associated with an increased risk of bleeding due to the antiplatelet effect of ASA, which interferes with normal hemostasis.

Interaction classifications may vary by region; the information above reflects standardized official regulatory documentation.

Advertisements

Mechanism of Action

How Цитрамон Ультра Works: Mechanism of Action

The drug's mechanism involves an integrated action across three primary biological domains, based on the coordinated activity of its active components.


️ Dual Modulation of Eicosanoid Synthesis

This domain focuses on the inhibition of Cyclooxygenase (COX) enzymes by Acetylsalicylic Acid (ASA) and Acetaminophen. ASA provides peripheral anti-eicosanoid action by irreversibly blocking COX, while Acetaminophen delivers complementary central modulation by inhibiting COX activity in the brain. This combined action modifies the early molecular steps that lead to the synthesis of prostaglandins, which are key chemical mediators in nociception and thermoregulation.


Central Purinergic and Vasomotor Control

This domain is driven by Caffeine's action as a non-selective antagonist of Adenosine receptors in the Central Nervous System (CNS). By blocking the inhibitory effects of adenosine, the mechanism increases neuronal activity and modulates central blood flow. This modulates overactive or dysregulated psychomotor processes and induces localized cerebral vasoconstriction.


Mechanistic Synergy and Systemic Integration

The overall physiological response emerges from the convergence of these distinct mechanisms: the combination of peripheral and central nociceptive pathway modulation is integrated with psychomotor stimulation from Caffeine. This functional integration provides a multi-modal adjustment of physiological responses, resulting in altered signaling dynamics within targeted pathways.

Advertisements

Dosage and Administration Information

The administration of this fixed-dose combination, which contains Acetaminophen, Acetylsalicylic Acid, and Caffeine, follows specific parameters for use. This guidance includes the appropriate administration route, dose limits, and time-related constraints for use in individuals aged 15 years and older.

Administration Protocol

The medication is intended for oral administration in the form of a tablet. It should be taken with a full glass of water to ensure proper delivery, and may be administered with food or milk if the user experiences stomach upset. A specific administration constraint advises the individual to remain in an upright position for at least 10 minutes following ingestion.

Feature Dosing and Scheduling Parameters
Route Oral (by mouth)
Standard Dose 1 tablet per single dose
Maximum Daily Dose 4 tablets per 24 hours
Minimum Interval 6 to 8 hours between doses
Age Restriction Adults and adolescents 15 years

Use-Context and Duration

The product is intended for intermittent use and is subject to duration constraints. Use for symptomatic relief of pain must not exceed 10 consecutive days, and use for fever management is limited to a maximum of 3 consecutive days. The schedule pattern is defined as as-needed (intermittent) use, up to 2 to 3 times per day, ensuring the mandatory minimum interval is observed. These instructions establish the standardized procedural steps for the medication’s use.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Цитрамон Ультра


Evidence from Clinical Trials for Acute Migraine Attacks

The research base for this triple-combination analgesic was studied for the symptomatic relief of acute migraine episodes in adults. The primary type of research conducted includes numerous double-blind, randomized, placebo-controlled trials (RCTs) and systematic reviews, which contribute to the broader evidence landscape.

In these trials, researchers primarily monitored outcomes related to physical discomfort over short-term observation periods. The studies examined endpoints such as the measurement of the percentage of patients who achieved a pain-free status at the 2-hour mark, and outcomes related to associated migraine symptoms (e.g., nausea, photophobia). The findings describe patterns observed in the studies compared to results reported with the placebo.

However, the evidence is largely focused on the short-term, single-dose pain outcomes for the acute attack. Data regarding patients outside the general adult demographic, such as older adults, remain insufficient for conclusive statements about these specific subgroups.


Research on Episodic Tension-Type Headache

The combination was evaluated in specific clinical research focused on conditions characterized by fluctuating or episodic manifestations, such as episodic tension-type headache. These studies often used crossover trial designs, and was applied in studies examining patient-reported experiences of pain and discomfort.

Research examined how symptoms evolved in the observed populations, with endpoints including achieving a pain-free state and the overall reduction in headache intensity over the first few hours. The primary limitation of this research is its focused nature on episodic manifestations. Existing studies provide limited insight into the management of conditions where symptoms may vary in intensity in a chronic, daily pattern.


Evidence Gaps and Areas for Further Research

The collective research landscape highlights several areas where certainty remains low or where more research may be necessary. One key research limitation frame is the limited information for long-term outcomes and the effects of repeated, frequent use of the combination, as most studies focus on a single event. Additionally, comparative evidence is lacking for direct, head-to-head performance against every other available analgesic drug on the market. These findings describe group patterns, not personal outcomes, and study results reflect the specific conditions under which they were conducted.

Key Studies & References Acetaminophen/Aspirin/Caffeine - StatPearls (NIH Bookshelf)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Цитрамон Ультра (FAQ)

Q: What is Цитрамон Ультра and what is it used for?

Цитрамон Ультра is a combination medication containing paracetamol, acetylsalicylic acid (aspirin), and caffeine. It is primarily used to relieve mild to moderate pain and reduce fever.


Q: How does the combination of ingredients in Цитрамон Ультра work?

The medication's effects are due to the combined action of its ingredients:

  • Paracetamol is an analgesic (pain reliever) and antipyretic (fever reducer).
  • Acetylsalicylic acid (aspirin) is also an analgesic and antipyretic, and it has anti-inflammatory effects.
  • Caffeine acts as an adjuvant, which means it enhances the pain-relieving effects of paracetamol and aspirin. It can also help relieve certain types of headaches by narrowing blood vessels.

Q: Can Цитрамон Ультра be used for headaches and migraines?

Yes, the combination of ingredients in Цитрамон Ультра is commonly used for the relief of tension headaches and has been shown to be effective for treating mild to moderate migraine attacks.


Q: Who should not take Цитрамон Ультра?

Цитрамон Ультра should not be taken by individuals with:

  • Known allergies to paracetamol, aspirin, caffeine, or other NSAIDs.
  • Stomach ulcers or a history of gastrointestinal bleeding, due to the aspirin content.
  • Severe liver or kidney disease.
  • Bleeding disorders or those taking blood thinners, as aspirin can increase the risk of bleeding.
  • Children and teenagers recovering from flu-like symptoms, chickenpox, or viral infections, due to the risk of Reye's syndrome associated with aspirin.

Q: What are the common side effects of Цитрамон Ультра?

Common side effects may include:

  • Stomach upset, heartburn, or nausea
  • Dizziness or nervousness
  • Insomnia or difficulty sleeping (due to caffeine)
  • Tinnitus (ringing in the ears), particularly with higher doses of aspirin
  • Allergic skin reactions

Q: Does Цитрамон Ультра interact with other medications?

Yes, it can interact with several medications, including:

  • Blood thinners (anticoagulants): Increased risk of bleeding due to aspirin.
  • Other NSAIDs: Increased risk of side effects, especially stomach bleeding.
  • Certain blood pressure medications.
  • Sedatives or central nervous system depressants.
  • Alcohol: Increases the risk of liver damage (due to paracetamol) and stomach irritation (due to aspirin).

It is important to inform a healthcare provider of all current medications before taking Цитрамон Ультра.


Q: What happens if I take too much Цитрамон Ультра?

An overdose of Цитрамон Ультра is dangerous and requires immediate medical attention. Key risks include:

  • Paracetamol overdose can cause severe and irreversible liver damage.
  • Aspirin overdose can lead to symptoms like severe nausea, vomiting, confusion, rapid breathing, and, in severe cases, seizures or coma.
  • Caffeine overdose can cause heart palpitations, severe anxiety, and tremors.

Do not exceed the recommended dosage.

Advertisements

How should Цитрамон Ультра be stored and disposed of?

Storage and Disposal of Цитрамон Ультра

Storage and disposal must strictly follow the conditions detailed in official regulatory documentation.

Storage Requirements

To ensure product stability, the medication must be stored at a temperature that does not exceed 25°C (77°F). Storage is required in a dry place and must be protected from light. The product has a labeled shelf-life of two years when stored correctly and must not be used after the expiration date printed on the package. As a mandatory safety requirement, the tablets must always be kept out of the reach of children.

Disposal Instructions

Official labeling instructs that unused or expired Цитрамон Ультра must not be discarded in wastewater or household waste. Disposal must occur according to local pharmaceutical waste regulations, typically by returning the product to a pharmacy or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Цитрамон Ультра found in:

A-Z Index: